| Literature DB >> 29323152 |
Aida Llucià-Valldeperas1, Ramon Bragós2, Carolina Soler-Botija3,4, Santiago Roura3,5,4, Carolina Gálvez-Montón3,4, Cristina Prat-Vidal3,4, Isaac Perea-Gil3, Antoni Bayes-Genis6,7,8,9.
Abstract
Mechanical conditioning is incompletely characterized for stimulating therapeutic cells within the physiological range. We sought to unravel the mechanism of action underlying mechanical conditioning of adipose tissue-derived progenitor cells (ATDPCs), both in vitro and in silico. Cardiac ATDPCs, grown on 3 different patterned surfaces, were mechanically stretched for 7 days at 1 Hz. A custom-designed, magnet-based, mechanical stimulator device was developed to apply ~10% mechanical stretching to monolayer cell cultures. Gene and protein analyses were performed for each cell type and condition. Cell supernatants were also collected to analyze secreted proteins and construct an artificial neural network. Gene and protein modulations were different for each surface pattern. After mechanostimulation, cardiac ATDPCs increased the expression of structural genes and there was a rising trend on cardiac transcription factors. Finally, secretome analyses revealed upregulation of proteins associated with both myocardial infarction and cardiac regeneration, such as regulators of the immune response, angiogenesis or cell adhesion. To conclude, mechanical conditioning of cardiac ATDPCs enhanced the expression of early and late cardiac genes in vitro. Additionally, in silico analyses of secreted proteins showed that mechanical stimulation of cardiac ATDPCs was highly associated with myocardial infarction and repair.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29323152 PMCID: PMC5764962 DOI: 10.1038/s41598-017-18799-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Mechanical stimulator design, characterization, and validation. (A) 3D view of the cell support system as reported in the patent PCT/EP 2012/061224. Two lateral structures, each containing an embedded magnet (part no. 126), are designed to exert pulling force on a thinner, central segment, which contains a rectangular cavity (pool, part no. 114) that holds a cell culture solution for growing the cell monolayer. (B) The Fort25 force transducer is shown, with a magnet attached to the sensor and aligned with the moving magnet; (B′) detail of the magnet attached to the force sensor lever. (C) Dimensions (in mm) of the cell support system as reported in the patent PCT/EP 2012/061224. The central segment containing the pool is the thinnest section of the whole structure; thus, it undergoes the greatest deformation. (D) Longitudinal and transverse measurements (in pixels) of the inner borders of the pool shows a ~10% elongation of the longitudinal borders. (E) Capture of the output differential voltage detected with the Fort25 sensor. (E′) The rise time slope is shown on a magnified scale. The rise and fall times were set to 100 ms, for a rough imitation of the ventricular pressure waveform. The small oscillations represent detection of residual, 50 Hz interference from the mains voltage supply (background noise).
Relative expression of cardiac markers for each surface condition in cardiac ATDPC cultures.
| Sample | Tbx5 | MEF2A | GATA-4 | α-actinin | Cx43 | SERCA2 | β-MyHC | cTnI | |
|---|---|---|---|---|---|---|---|---|---|
| Vertical | cardiac ATDPCs Con | 0.003 ± 0.001 | 0.089 ± 0.018 | 0.428 ± 0.196 | 2.445 ± 1.089 | 0.705 ± 0.253 | 0.397 ± 0.237 | 0.095 ± 0.049 | 0.693 ± 0.555 |
| cardiac ATDPCs MS | 0.004 ± 0.002 | 0.169 ± 0.089 | 1.209 ± 0.378 | 2.326 ± 1.109 | 1.371 ± 0.949 | 0.551 ± 0.413 | 0.181 ± 0.114 | 0.964 ± 0.620 | |
| Ratio MS/Con |
|
|
|
|
|
|
|
| |
| 0.653 | 0.410 |
| 0.753 | 0.517 | 0.756 | 0.443 | 0.940 | ||
| Horizontal | cardiac ATDPCs Con | 0.004 ± 0.000 | 0.031 ± 0.007 | 0.030 ± 0.005 | 0.180 ± 0.011 | 0.150 ± 0.043 | 0.046 ± 0.007 | 7.8·10−6 ± 5.4·10−6 | 5.1·10−6 ± 2·10−6 |
| cardiac ATDPCs MS | 0.005 ± 0.000 | 0.033 ± 0.002 | 0.035 ± 0.003 | 0.286 ± 0.064 | 0.139 ± 0.042 | 0.063 ± 0.005 | 1.8·10−5 ± 1.5·10−5 | 1.4·10−5 ± 1.9·10−6 | |
| Ratio MS/Con |
|
|
|
|
|
|
|
| |
|
| 0.854 | 0.397 | 0.181 | 0.865 | 0.110 | 0.419 |
| ||
| Smooth | cardiac ATDPCs Con | 0.001 ± 0.000 | 0.029 ± 0.007 | 0.050 ± 0.008 | 0.213 ± 0.010 | 0.228 ± 0.100 | 0.091 ± 0.015 | 1.7·10−5 ± 1.6·10−5 | 7.6·10−6 ± 5.1·10−6 |
| cardiac ATDPCs MS | 0.001 ± 0.000 | 0.045 ± 0.014 | 0.067 ± 0.013 | 0.362 ± 0.018 | 0.262 ± 0.101 | 0.127 ± 0.019 | 2·10−5 ± 1.5·10−5 | 1.2·10−5 ± 1.2·10−5 | |
| Ratio MS/Con |
|
|
|
|
|
|
|
| |
| 0.217 | 0.404 | 0.312 |
| 0.817 | 0.198 | 0.848 | 0.662 |
Gene expressions were analyzed in duplicate for comparisons between mechanically stimulated (MS) and control (Con) samples. Relative expression (2−ΔCT) and fold-changes in expression (MS/Con) are shown for cardiomyogenic genes. Values were normalized to GAPDH expression and represent the mean ± SEM for at least 4 independent experiments. *P < 0.05 (significant) and #P < 0.10 (trend).
Figure 2Protein expression profiles after mechanical stimulation. Immunohistochemical staining shows expression of proteins in cardiac (left) and subcutaneous (right) ATDPCs grown on vertical, horizontal, and smooth patterned surfaces, as indicated (diagrams in the top, centers indicate surface patterns with respect to the magnets in the cell support system). Control (first and third columns) and mechanostimulated (second and fourth columns) were stained, as indicated, to show expression of (top rows) actin F (phalloidin staining, red) and Cx43 (green); (center rows) SERCA2 (red) and MEF2 (green); and (bottom rows) sarcomeric α-actinin (red) and GATA-4 (green). Nuclei were counterstained with DAPI (blue) in A–D,K,L,M–P,W,X,Y–AB,AI,AJ). Scale bars = 50 µm.
Protein quantification determined from immunostaining of the main cardiac markers for each condition and cell type.
| Sample | MEF2A | GATA-4 | α-actinin | Cx43 | SERCA2 | actinF | |
|---|---|---|---|---|---|---|---|
| Vertical | cardiac ATDPCs Con | 1.125 ± 0.093 | 0.979 ± 0.114 | 0.958 ± 0.088 | 0.449 ± 0.071 | 1.325 ± 0.110 | 0.649 ± 0.069 |
| cardiac ATDPCs MS | 1.289 ± 0.179 | 0.729 ± 0.016 | 0.705 ± 0.024 | 0.678 ± 0.028 | 2.065 ± 0.184 | 0.729 ± 0.019 | |
| Ratio MS/Con |
|
|
|
|
|
| |
| 0.423 |
|
|
|
| 0.301 | ||
| Horizontal | cardiac ATDPCs Con | 1.150 ± 0.146 | 0.654 ± 0.024 | 1.113 ± 0.014 | 0.448 ± 0.117 | 1.213 ± 0.054 | 1.233 ± 0.270 |
| cardiac ATDPCs MS | 0.732 ± 0.071 | 0.662 ± 0.020 | 1.499 ± 0.051 | 1.080 ± 0.020 | 1.521 ± 0.080 | 1.425 ± 0.044 | |
| Ratio MS/Con |
|
|
|
|
|
| |
|
| 0.880 |
|
|
| 0.504 | ||
| Smooth | cardiac ATDPCs Con | 0.435 ± 0.012 | 0.725 ± 0.070 | 1.126 ± 0.086 | 0.858 ± 0.068 | 0.435 ± 0.017 | 1.330 ± 0.095 |
| cardiac ATDPCs MS | 0.639 ± 0.015 | 0.910 ± 0.088 | 2.568 ± 0.215 | 1.794 ± 0.160 | 0.975 ± 0.027 | 5.190 ± 0.617 | |
| Ratio MS/Con |
|
|
|
|
|
| |
|
| 0.123 |
|
|
|
| ||
| Vertical | subcutaneous ATDPCs Con | 0.841 ± 0.047 | NA | 1.403 ± 0.169 | 0.776 ± 0.147 | 0.613 ± 0.048 | 0.751 ± 0.108 |
| subcutaneous ATDPCs MS | 0.784 ± 0.096 | NA | 1.535 ± 0.367 | 1.048 ± 0.110 | 0.508 ± 0.043 | 1.677 ± 0.123 | |
| Ratio MS/Con |
|
|
|
|
| ||
| 0.562 | 0.726 | 0.197 | 0.110 |
| |||
| Horizontal | subcutaneous ATDPCs Con | 0.718 ± 0.058 | NA | 1.223 ± 0.043 | 0.972 ± 0.013 | 1.572 ± 0.047 | 1.287 ± 0.095 |
| subcutaneous ATDPCs MS | 0.711 ± 0.017 | NA | 1.172 ± 0.043 | 1.005 ± 0.037 | 1.178 ± 0.059 | 1.406 ± 0.057 | |
| Ratio MS/Con |
|
|
|
|
| ||
| 0.891 | 0.492 | 0.405 |
| 0.264 | |||
| Smooth | subcutaneous ATDPCs Con | 0.662 ± 0.048 | NA | 1.194 ± 0.099 | 0.752 ± 0.095 | 1.542 ± 0.366 | 1.955 ± 0.254 |
| subcutaneous ATDPCs MS | 0.965 ± 0.063 | NA | 1.121 ± 0.080 | 1.520 ± 0.112 | 2.377 ± 0.158 | 2.823 ± 0.229 | |
| Ratio MS/Con |
|
|
|
|
| ||
|
| 0.568 |
|
|
|
Fluorescence intensity values were normalized to DAPI intensity and are shown as the mean ± SEM. Con: control, MS: mechanostimulated. *P < 0.05 (significant) and #P < 0.10 (trend). NA, not applicable.
Results from the pairwise, trimmed, mean normalization analysis for each condition.
| Experiment | Protein name | UNIPROT | MS | Effector | # Linked Effectors |
|---|---|---|---|---|---|
| Cardiac ATDPCs vertical | Complement C3 | P01024 | 1.017 | Inflammation | 11 |
| Tissue inhibitor of metalloproteinases 1 (TIMP-1) | P01033 | 0.911 | LV ECM remodelling | 4 | |
| Fibronectin (FN) | P02751 | 1.004 | LV ECM remodelling | 4 | |
| Vimentin | P08670 | 0.974 | Intermediary | 8 | |
| Collagen type VI α-1 chain | P12109 | 1.169 | LV ECM remodelling | 7 | |
| Cardiac ATDPCs horizontal | Stromal interaction molecule 2 | Q9P246 |
| — | 0 |
| Cardiac ATDPCs smooth | Tissue inhibitor of metalloproteinases 1 (TIMP-1) | P01033 | 1.002 | LV ECM remodelling | 4 |
| Matrix metalloproteinase 2 (MMP-2) | P08253 | 1.036 | LV ECM remodelling | 20 | |
| Collagen type VI α-1 chain | P12109 | 1.097 | LV ECM remodelling | 7 | |
| Pentraxin-related protein 3 (PTX3) | P26022 | 1.166 | Intermediary | 1 | |
| Follistatin-related protein 1 (FSTL1) | Q12841 | 0.994 | Proliferation | 4 | |
| Subcutaneous ATDPCs vertical | Tissue inhibitor of metalloproteinases 1 (TIMP-1) | P01033 | 1.063 | LV ECM remodelling | 4 |
| Fibronectin (FN) | P02751 | 1.012 | LV ECM remodelling | 4 | |
| Matrix metalloproteinase 2 (MMP-2) | P08253 | 0.964 | LV ECM remodelling | 20 | |
| Stromal interaction molecule 2 | Q9P246 | 1.028 | — | 0 | |
| Subcutaneous ATDPCs horizontal | α-2-macroglobulin (α-2-M) | P01023 | 1.008 | Intermediary | 10 |
| Thioredoxin (TXN) | P10599 | 1.038 | Intermediary | 5 | |
| Collagen type VI α-1 chain | P12109 | 0.824 | LV ECM remodelling | 7 | |
| Subcutaneous ATDPCs smooth | Collagen type I α-1 chain | P02452 | 1.031 | Intermediary | 7 |
| Collagen type I α-2 chain | P08123 | 1.017 | Intermediary | 5 | |
| Vimentin | P08670 | 1.006 | Intermediary | 8 | |
| Complement C1s subcomponent | P09871 | 1.089 | — | 0 | |
| Transforming growth factor-β-induced protein ig-h3 | Q15582 | 0.993 | — | 0 | |
| Nuclear pore complex protein (Nup205) | Q92621 | 1.009 | Intermediary | 2 |
Proteins that showed significant differential expression in mechanostimulated (MS) and control (Con) cells are shown with their name and UNIPROT code. The relative protein abundance is shown in the “MS vs. Con” column. The “Effector” column indicates the protein category. The “# Linked Effectors” column indicates the number of effector proteins linked to the protein of interest.
Figure 3Secretome analysis. (A,B) Venn’s diagrams of differentially expressed proteins in (A) cardiac ATDPCs and (B) subcutaneous ATDPCs. (C–E) Protein networks for (C) cardiac seeded on vertical patterned surfaces, (D) subcutaneous ATDPCs seeded on horizontal patterned surfaces, and (E) cardiac ATDPCs grown on a smooth surface. Red octagons are secretome proteins; red diamonds are secretome proteins that are also effectors of MI or cardiac regeneration; yellow circles are effectors of MI or cardiac regeneration that are linked to the secretome proteins; the blue circle indicates a protein included in the Gene Ontology (GO) terms that was linked to the indicated secretome protein; and green circles indicate proteins or effectors linked to the secretome proteins. (F) Fibronectin protein expression (green) in mechanically stimulated cardiac ATDPCs grown on vertical patterned surfaces. (G) Vimentin protein expression (green) in mechanically stimulated subcutaneous ATDPCs grown on smooth surfaces. Nuclei were counterstained with DAPI (blue). Scale bars = 50 µm.
Artificial Neural Network prediction values for myocardial infarction (MI) and cardiac regeneration functions.
| Treatment | Myocardial Infarction | ||||
|---|---|---|---|---|---|
| MI | MI Inflammation | Cardiomyocyte cell death | LV ECM remodelling | ||
| Cardiac ATDPCs vertical |
|
|
|
| |
| Cardiac ATDPCs horizontal | 4.96% | 13.20% | 57.91% | 21.92% | |
| Cardiac ATDPCs smooth | 79.07% | 49.59% | 11.96% | 88.26% | |
| Subcutaneous ATDPCs vertical | 81.84% | 32.05% | 5.24% | 82.73% | |
| Subcutaneous ATDPCs horizontal |
|
|
|
| |
| Subcutaneous ATDPCs smooth | 38.13% | 51.36% | 39.83% | 29.14% | |
|
|
| ||||
|
|
|
|
|
| |
| Cardiac ATDPCs vertical | 15.94% | 26.80% | 5.32% | 14.04% | 5.39% |
| Cardiac ATDPCs horizontal | 5.29% | 5.07% | 7.44% | 19.33% | 5.05% |
| Cardiac ATDPCs smooth |
|
|
|
| 69.55% |
| Subcutaneous ATDPCs vertical | 18.72% | 11.19% | 5.46% | 9.32% | 8.97% |
| Subcutaneous ATDPCs horizontal |
|
|
|
| 15.41% |
| Subcutaneous ATDPCs smooth | 39.29% | 57.89% | 6.64% | 7.20% | 6.08% |
Bold values are the most relevant for each cell type and condition.